Key clinical point: Adding trastuzumab to carboplatin/paclitaxel improves survival in patients with advanced or recurrent HER2/Neu-positive uterine serous carcinoma.

Major finding: At a median follow-up of 25.9 months, the median progression-free survival was 12.9 months in patients who received trastuzumab plus carboplatin/paclitaxel and 8.0 months in patients who received only carboplatin/paclitaxel (hazard ratio, 0.46; P = .005). The median overall survival was 29.6 months and 24.4 months, respectively (HR, 0.58; P = .046).

Study details: An updated analysis of a phase 2 trial including 58 patients.

Disclosures: The trial was sponsored by Yale University in collaboration with Genentech. Dr. Nickles Fader reported having no disclosures.